A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

NCT03671044 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

657

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Nanosomal Docetaxel Lipid Suspension (75 mg/m2)
DRUG: Nanosomal Docetaxel Lipid Suspension (100 mg/m2)
DRUG: Taxotere® (100 mg/m2)

Sponsor

Jina Pharmaceuticals Inc.

Collaborators

[object Object]
[object Object]